OABI trades 55.6% below Wall Street's consensus target of $4.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes OABI achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 30, 2026, OmniAb, Inc. (OABI) has a Wall Street consensus price target of $4.00, based on estimates from 9 covering analysts. With the stock currently trading at $2.57, this represents a potential upside of +55.6%. The company has a market capitalization of $306M.
Analyst price targets range from a low of $4.00 to a high of $4.00, representing a 0% spread in expectations. The median target of $4.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, OABI trades at a trailing P/E of -4.5x. Analysts expect EPS to grow +3.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
HALOHalozyme Therapeutics, Inc. | $9.2B | $77.18 | $88.25 | +14.3% | Buy | 9.5x | 27 |
ADCTADC Therapeutics S.A. | $131M | $1.03 | $3.50 | +239.8% | Hold | — | 12 |
RCUSArcus Biosciences, Inc. | $3.1B | $31.08 | $31.00 | -0.3% | Buy | — | 18 |
IMVTImmunovant, Inc. | $7.9B | $38.51 | $45.00 | +16.9% | Buy | — | 23 |
REGNRegeneron Pharmaceuticals, Inc. | $65.6B | $631.81 | $836.00 | +32.3% | Buy | 13.6x | 48 |
ABCLAbCellera Biologics Inc. | $2.5B | $8.12 | $7.50 | -7.6% | Buy | — | 11 |
TWSTTwist Bioscience Corporation | $6.1B | $98.36 | $78.33 | -20.4% | Buy | — | 13 |
SEERSeer, Inc. | $91M | $1.66 | $4.00 | +141.0% | Hold | — | 4 |
BEAMBeam Therapeutics Inc. | $3.6B | $34.95 | $48.00 | +37.3% | Buy | — | 27 |
TMOThermo Fisher Scientific Inc. | $188.2B | $506.42 | $592.45 | +17.0% | Buy | 20.4x | 42 |
Quick answers to the most common questions about buying OABI stock.
The consensus Wall Street price target for OABI is $4, representing 55.6% upside from the current price of $2.57. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
OABI has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $4 implies 55.6% upside from current levels.
OABI's current price is $2.57 with a consensus target of $4 (55.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $4 for OABI, while the most conservative target is $4. The consensus of $4 represents the median expectation. These targets typically reflect 12-month expectations.
OABI is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month OABI stock forecast based on 9 Wall Street analysts shows a consensus price target of $4, with estimates ranging from $4 (bear case) to $4 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on OABI, with a "Buy" consensus rating and $4 price target (55.6% upside). 9 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
OABI analyst price targets range from $4 to $4, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $4 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.